Citigroup Inc Tcr2 Therapeutics Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$1.0 - $1.62 $89,998 - $145,796	-89,998 Reduced 19.01%	383,486 $575,000
Q4 2022 Feb 09, 2023	BUY	$0.83 - $1.44 $392,610 - $681,156	473,025 Added 103055.56%	473,484 $473,000
Q3 2022 Nov 10, 2022	SELL	$1.86 - $3.75 $1,071 - $2,160	-576 Reduced 55.65%	459 $1,000
Q2 2022 Aug 10, 2022	SELL	$2.11 - $2.94 $2,335 - $3,254	-1,107 Reduced 51.68%	1,035 $3,000
Q1 2022 May 12, 2022	SELL	$2.4 - $4.71 $16,161 - $31,717	-6,734 Reduced 75.87%	2,142 $6,000
Q4 2021 Feb 10, 2022	SELL	$4.58 - $8.34 $188,453 - $343,165	-41,147 Reduced 82.26%	8,876 $41,000
Q3 2021 Nov 10, 2021	BUY	$8.44 - $18.35 $422,194 - $917,922	50,023 New	50,023 $426,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.